Journal of Spine

ISSN: 2165-7939

Open Access

Effect of Siponimod on Brain and Spinal Cord Imaging Markers of Neurodegeneration in a Model of Demyelination Caused by Theiler′s Murine Encephalomyelitis


Riyour Suloo*

Neuroinflammatory demyelinating diseases, such as Multiple Sclerosis (MS), can lead to significant neurodegeneration, causing debilitating neurological symptoms. Siponimod, a selective sphingosine-1-phosphate receptor modulator, has shown promise in the treatment of MS by modulating immune cell trafficking and reducing neuroinflammation. In this study, we investigated the effect of siponimod on brain and spinal cord imaging markers of neurodegeneration using a murine model of demyelination caused by Theiler's Murine Encephalomyelitis Virus (TMEV). Through comprehensive neuroimaging analysis, we evaluated the impact of siponimod on demyelination-associated neurodegeneration, providing insights into its potential as a therapeutic intervention in demyelinating diseases.


Share this article

Google Scholar citation report
Citations: 2022

Journal of Spine received 2022 citations as per Google Scholar report

Journal of Spine peer review process verified at publons

Indexed In

arrow_upward arrow_upward